Silexion Therapeutics Corp SEC filings SLXNW
Silexion Therapeutics Corp has 279 filings in SEC EDGAR's recent list, going back to May 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Oct 28, 2026 | — |
| 424B3 | Prospectus | Sep 29, 2026 | — |
| 424B4 | Prospectus | Aug 13, 2026 | — |
| S-1/A | Amended registration statement | Aug 10, 2026 | — |
| S-1 | Registration statement | Aug 7, 2026 | — |
| 424B3 | Prospectus | Jun 18, 2026 | — |
| S-3 | Shelf registration | Jun 12, 2026 | — |
| S-8 | Employee stock plan registration | May 28, 2026 | — |
| POS AM | Filing | May 7, 2026 | — |
| POS AM | Filing | May 7, 2026 | — |
| S-8 | Employee stock plan registration | Feb 19, 2026 | — |
| S-3 | Shelf registration | Oct 31, 2025 | — |
| S-3 | Shelf registration | Sep 26, 2025 | — |
| 424B4 | Prospectus | Sep 12, 2025 | — |
| S-1 | Registration statement | Sep 5, 2025 | — |
| 424B3 | Prospectus | Sep 4, 2025 | — |
| S-1 | Registration statement | Aug 26, 2025 | — |
| S-8 | Employee stock plan registration | Aug 20, 2025 | — |
| 424B3 | Prospectus | Aug 12, 2025 | — |
| 424B3 | Prospectus | Aug 12, 2025 | — |
| 424B3 | Prospectus | Aug 12, 2025 | — |
| 424B3 | Prospectus | Aug 1, 2025 | — |
| 424B3 | Prospectus | Aug 1, 2025 | — |
| POS AM | Filing | May 28, 2025 | — |
| 424B3 | Prospectus | May 13, 2025 | — |
| 424B3 | Prospectus | May 13, 2025 | — |
| 424B3 | Prospectus | May 6, 2025 | — |
| POS AM | Filing | Apr 29, 2025 | — |
| 424B3 | Prospectus | Apr 29, 2025 | — |
| POS AM | Filing | Apr 23, 2025 | — |
| POS AM | Filing | Apr 10, 2025 | — |
| POS AM | Filing | Apr 10, 2025 | — |
| 424B3 | Prospectus | Apr 1, 2025 | — |
| S-1/A | Amended registration statement | Mar 27, 2025 | — |
| S-8 | Employee stock plan registration | Mar 18, 2025 | — |
| 424B3 | Prospectus | Mar 14, 2025 | — |
| S-1 | Registration statement | Feb 12, 2025 | — |
| 424B4 | Prospectus | Jan 17, 2025 | — |
| S-1/A | Amended registration statement | Jan 14, 2025 | — |
| S-1/A | Amended registration statement | Jan 14, 2025 | — |
| 424B3 | Prospectus | Dec 10, 2024 | — |
| 424B3 | Prospectus | Dec 10, 2024 | — |
| 424B3 | Prospectus | Nov 29, 2024 | — |
| 424B3 | Prospectus | Nov 29, 2024 | — |
| 424B3 | Prospectus | Nov 22, 2024 | — |
| 424B3 | Prospectus | Nov 22, 2024 | — |
| 424B3 | Prospectus | Nov 19, 2024 | — |
| 424B3 | Prospectus | Nov 19, 2024 | — |
| S-1 | Registration statement | Oct 31, 2024 | — |
| 424B3 | Prospectus | Oct 16, 2024 | — |
| S-1 | Registration statement | Oct 9, 2024 | — |
| 424B3 | Prospectus | Sep 19, 2024 | — |
| 424B3 | Prospectus | Sep 18, 2024 | — |
| S-1 | Registration statement | Sep 10, 2024 | — |
| 424B3 | Prospectus | Jul 17, 2024 | — |
| S-4/A | Registration statement | Jul 12, 2024 | — |
| S-4/A | Registration statement | Jul 5, 2024 | — |
| S-4/A | Registration statement | Jun 24, 2024 | — |
| S-4 | Registration for a merger or exchange | May 9, 2024 | — |
Showing 59 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SLXN (Nasdaq), SLXNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022416
- Former names
- Biomotion Sciences (until Aug 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.